Global Gemcitabine Market Growth 2023-2029

Global Gemcitabine Market Growth 2023-2029

Gemcitabine (CAS 95058-81-4), C9H11F2N3O4, the formula weight is 263.2, and its form is white to yellow powder.

LPI (LP Information)' newest research report, the “Gemcitabine Industry Forecast” looks at past sales and reviews total world Gemcitabine sales in 2022, providing a comprehensive analysis by region and market sector of projected Gemcitabine sales for 2023 through 2029. With Gemcitabine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gemcitabine industry.

This Insight Report provides a comprehensive analysis of the global Gemcitabine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gemcitabine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Gemcitabine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gemcitabine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gemcitabine.

The global Gemcitabine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Gemcitabine is used as a second-line treatment for patients with advanced pancreatic cancer after fluorouracil failure, and can improve the quality of life of patients. Secondly, it is a first-line application for locally advanced (stage III) and already metastatic (stage IV) non-small cell lung cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of Gemcitabine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
1g/Vial
200mg/Vial

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lilly France
Hansoh Pharma
Hisun Pharma
Pude Pharma
Qilu Pharma
Jari Pharma
HPGC
Yibantian Pharma
Actavis
Accord Healthcare
Mylan
Novartis
Salius Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Gemcitabine market?

What factors are driving Gemcitabine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Gemcitabine market opportunities vary by end market size?

How does Gemcitabine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.